Literature DB >> 3039047

Natural killer cells are not required for interferon-mediated prophylaxis against vaccinia or murine cytomegalovirus infections.

J F Bukowski, K W McIntyre, H Yang, R M Welsh.   

Abstract

Natural killer (NK) cell-depleted or control mice were treated prophylactically with polyinosinic: polycytidylic acid (polyI: polyC) or purified beta interferon (IFN) and then infected with either vaccinia virus or murine cytomegalovirus. NK cell depletion alone enhanced virus titres in the spleen and peritoneal cavity. However, poly I: polyC and IFN inhibited virus replication equally well in control and NK cell-depleted mice. This suggests that prophylactic IFN treatment mediates antiviral effects independently of NK cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3039047     DOI: 10.1099/0022-1317-68-8-2219

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  4 in total

1.  Broad-spectrum in vivo antiviral activity of 7-thia-8-oxoguanosine, a novel immunopotentiating agent.

Authors:  D F Smee; H A Alaghamandan; H B Cottam; B S Sharma; W B Jolley; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Immunoenhancing properties and antiviral activity of 7-deazaguanosine in mice.

Authors:  D F Smee; H A Alaghamandan; J Gilbert; R A Burger; A Jin; B S Sharma; K Ramasamy; G R Revankar; H B Cottam; W B Jolley
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

3.  Effects of virally expressed interleukin-10 on vaccinia virus infection in mice.

Authors:  M G Kurilla; S Swaminathan; R M Welsh; E Kieff; R R Brutkiewicz
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

4.  Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity.

Authors:  Patrick C Reading; Geoffrey L Smith
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.